BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avicena Group, Inc. to Present at 4th Annual Biotechnology Industry Organization (BIO) InvestorForum Conference Expansion of Drug Pipeline and Advancement of Clinical Programs


10/9/2007 11:39:31 AM

PALO ALTO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Avicena Group, Inc. , a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today that it will be a presenting company at the 4th Annual BIO InvestorForum Conference to be held October 9-11, 2007 at the Palace Hotel of San Francisco. The company's chief executive officer, Belinda Tsao-Nivaggioli, Ph.D., will present an overview of the company and its clinical programs, including an update on activities to build its drug pipeline and investigate new delivery vehicles to enhance the bioavailability of its lead drug candidates. Dr. Tsao-Nivaggioli will be presenting on Thursday, October 11 at 10:30 a.m. (EDT) in the Twin Peaks North room. For more information on this event please visit: http://www.investorforum.bio.org/.

To participate in a live audio and visual webcast of Dr. Tsao-Nivaggioli's presentation please log onto Avicena's corporate website at http://www.avicenagroup.com at least fifteen minutes prior to the start of the presentation to download any necessary materials. An archive of this event will be available in the investor relations section of the website for 30 days.

ABOUT AVICENA

Avicena Group, Inc. is a Palo Alto, California based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

sephraim@theruthgroup.comjmccargo@theruthgroup.com or jrando@theruthgroup.com

CONTACT: Sara Ephraim (investors), +1-646-536-7002,
sephraim@theruthgroup.com, or, media, Janine McCargo, +1-646-536-7033,
jmccargo@theruthgroup.com, or Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, all of The Ruth Group, for Avicena Group, Inc.

Web site: http://www.avicenagroup.com/
http://www.investorforum.bio.org/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES